In collaboration with Eurofins Viracor Biopharma, Eurofins Central Laboratory in Shanghai, China, has expanded its respiratory syncytial virus (RSV) detection capacity since 2021 to support the rapid needs of clients for clinical research on respiratory syncytial virus (RSV). The Eurofins Central Laboratory sites in the Netherlands and Singapore have completed the installation of this testing platform in 2021 and the Eurofins Central Laboratory in Shanghai will complete the installation of this platform in July this year.
By August, the Eurofins companies will be providing clients with global solutions for the integration of respiratory syncytial virus (RSV) research and testing. This will significantly reduce the sponsor’s research budget and improve specimen quality and integrity by reducing unnecessary transport.
About Respiratory Viral Pathogen Panel
The Eurofins Central Laboratory respiratory syncytial virus (RSV) detection platform is Genmark ePlex. The Respiratory Viral Panel detects 11 viral pathogens using TEM-PCRTM (Target Enriched Multiplex Polymerase Chain Reaction) technology – a multiplex PCR amplification technology to detect multiple targets simultaneously. Multiple target panel testing helps identify co-infections, provides physicians with valuable diagnostic insight into unknown causes of infection, reduces unnecessary antibiotic administration and hospital-acquired infections, allows for molecular testing in patients with concurrent therapy, and more targeted therapy for better patient management and overall reduced hospital costs.
Human respiratory syncytial virus (RSV), a negative-sense, single-stranded RNA, causes a variety of respiratory illnesses. In at-risk infants and children, it can cause bronchitis, croup, and lower respiratory infections like bronchiolitis and pneumonia. Premature infants, very young infants, and those with chronic (always present) lung or heart disease or with suppressed (weakened) immune systems have a greater chance of having a more severe infection such as a lower respiratory tract infection. Symptomatic RSV infections may occur in adults, particularly in healthcare workers or caretakers of small children. High-risk adults, such as those with certain chronic illnesses or immunosuppression, may have more severe symptoms consistent with a lower respiratory tract infection, such as pneumonia.
About Eurofins Central Laboratory China Co., Ltd.
Joining Eurofins in 2001, our Central Laboratory network is committed to providing end-to-end clinical laboratory solutions with global standards. In 2003, we began to serve clinical research in China with the help of our partners. In order to better support domestic clinical trials, or global trials involving Chinese subjects in the study protocol, the Eurofins Central Laboratory has been in operation in Shanghai since April 2008, and it is the fourth central laboratory in addition to our sites in the Netherlands, the United States and Singapore. In 2019, Eurofins Central Laboratory Shanghai expanded its service offering by including the manufacturing and shipping of specimen collection kits in China. In order to meet the increasingly complex requirements of the research program, the Laboratory was relocated to the group’s headquarters in Pujiang, Shanghai in 2021, nearly doubling in size to further facilitate the addition of key capabilities and business expansion.
In addition to standard safety testing in support of clinical trials, the Shanghai Laboratory is also providing biomarker testing. Our newly installed MSD platform can be used for biomarker analysis and immunoassay of multiplex biomarkers. The Shanghai Laboratory is also offering processing and transportation services for PBMC (peripheral blood mononuclear cells) at different levels. We ensure effective collection, processing, cryopreservation, and transportation of PBMC samples to ensure sample stability. In addition, the Eurofins Central Laboratories, including Shanghai Laboratory, have global flow cytometry capabilities. DNA extraction and RT-PCR platforms are planned to be added to the Shanghai Lab capabilities soon. The expanded capacity of laboratory testing services will allow more and more complex solutions to be offered to customers and improve the efficiency of the drug development life cycle, consistent with the regulatory environment in China.
About Eurofins Viracor BioPharma
With cutting-edge technology and a specialized team of R&D scientists, Eurofins Viracor BioPharma has been supporting clients through multiple phases of drug development for over thirty-five years.
We’re experts in developing, customizing, and validating assays for complex clinical research testing. Our broad laboratory capabilities offer services covering infectious disease, immune response, allergy hypersensitivity, oncology, and more.
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific’s management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantees can be made as to their completeness or validity.